Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.

MLA

Oliveira, Mafalda, et al. “Capivasertib and Fulvestrant for Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (CAPItello-291): Patient-Reported Outcomes from a Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial.” The Lancet. Oncology, vol. 25, no. 9, Sept. 2024, pp. 1231–44. EBSCOhost, https://doi.org/10.1016/S1470-2045(24)00373-5.

APA

Oliveira, M., Rugo, H. S., Howell, S. J., Dalenc, F., Cortes, J., Gomez, H. L., Hu, X., Toi, M., Jhaveri, K., Krivorotko, P., Loibl, S., Morales Murillo, S., Okera, M., Nowecki, Z., Park, Y. H., Sohn, J. H., Tokunaga, E., Yousef, S., Zhukova, L., … Turner, N. C. (2024). Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 25(9), 1231–1244. https://doi.org/10.1016/S1470-2045(24)00373-5

Chicago

Oliveira, Mafalda, Hope S Rugo, Sacha J Howell, Florence Dalenc, Javier Cortes, Henry L Gomez, Xichun Hu, et al. 2024. “Capivasertib and Fulvestrant for Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (CAPItello-291): Patient-Reported Outcomes from a Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial.” The Lancet. Oncology 25 (9): 1231–44. doi:10.1016/S1470-2045(24)00373-5.